Staging preview: health content pending qualified review
D2C Peptides

Dosage information

CJC-1295 + Ipamorelin dosage

No dose of CJC-1295 + Ipamorelin is established for people, and no published human study has dosed the blend or CJC-1295 without DAC.131718 The figures on this page are what researchers gave in trials of CJC-1295 with DAC, a different form, and of ipamorelin given by vein to people or under the skin to rats.4710

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

No established dose

Three facts frame every number on this page.

  1. No human dosing study has been published for CJC-1295 without DAC or for CJC-1295 combined with ipamorelin, and FDA found no animal pharmacology study of the no-DAC form.131718 A 2026 primer mentions rodent results for the combination, but the steroid-model rat study that measured the same muscle outcome gave ipamorelin alone (Andersen 2001, below).1512
  2. The CJC-1295 in published human trials is the DAC form, and FDA says those results cannot be extrapolated to the form without DAC.1
  3. In people, ipamorelin has been given by vein, plus one nasal dose to a single volunteer in an anti-doping study.214 FDA found no human data for ipamorelin injected under the skin.2

FDA's review lists the wide range of doses quoted online, and a 2026 review stresses that such online regimens are not evidence-based.13 A 2026 primer for sports medicine physicians adds that the indications, dosing, frequency and duration of these peptides remain unknown.15

Doses used in published studies

Each row shows what one study gave, to whom and by which route. These figures describe the studies; they are not instructions.

Study Compound Who Route What was given Length
Teichman 2006, two phase 1 trials41 CJC-1295 with DAC Healthy adults aged 21 to 61 Under the skin Single doses from 30 to 250 mcg/kg in one trial; two or three doses of 20 to 60 mcg/kg, a week or two apart, in the other Single dose; 28 and 49 days
Ionescu and Frohman 200651 CJC-1295 with DAC 12 healthy men aged 20 to 40 Under the skin One dose of 60 mcg/kg (4 men) or 90 mcg/kg (8 men) Single dose, sampled 1 week later
ConjuChem phase 2, NCT0026752716 CJC-1295 with DAC Adults with HIV-associated visceral obesity Weekly injections Escalating over 3 weeks (60, 90 and 120 mcg/kg, or 60, 120 and 240 mcg/kg), with 9 more weeks planned Stopped in 2006; unpublished, known from anecdotal reports cited by FDA
Gobburu 19997 Ipamorelin Healthy men, 8 per dose level 15-minute IV infusion 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg Single dose
Beck 2014, phase 28 Ipamorelin 114 adults after bowel resection IV infusion 0.03 mg/kg twice daily Day 1 after surgery to day 7 or discharge
NCT01280344, phase 29 Ipamorelin 320 adults after open bowel resection IV infusion 0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily, vs placebo Up to 10 days; no results posted
Johansen 199910 Ipamorelin Adult female rats Under the skin, three times daily 18, 90 or 450 mcg per day 15 days
Svensson 200011 Ipamorelin 13-week-old female rats Continuous pump under the skin 0.5 mg/kg per day 12 weeks
Andersen 200112 Ipamorelin 8-month-old female rats, some also given a steroid Under the skin, three times daily 100 mcg/kg 3 months

How to read these numbers

  • Weight-based amounts: every human figure above is per kilogram of body weight, and the studies measured hormone responses or recovery after surgery, not long-term outcomes.478
  • Different molecules, different timing: the DAC form had an estimated half-life of 5.8 to 8.1 days, and its trials spaced injections a week or more apart.4 No human half-life has been reported for CJC-1295 without DAC.3 For scale only, native GHRH(1-29) had a disappearance half-time of 4.3 minutes in 10 healthy men, and a version with just one of the four swaps (D-alanine at position 2) lasted 6.7 minutes.13
  • A short ipamorelin pulse: after a 15-minute IV infusion, growth hormone peaked at about 0.67 hours, ipamorelin's terminal half-life was about 2 hours, and growth hormone was very low again by 6 hours.72 In FDA's summary, the lowest dose produced negligible growth hormone and was left out of the analysis.2
  • Rat studies: the amounts given to rats describe those experiments only. All three used female rats, and one group was also given a steroid.101112

Product identity and dose

A dose is only as meaningful as the substance in the vial. FDA warns that inconsistent naming of CJC-1295 forms could lead to a person receiving a different substance than intended, and notes that research sellers do not say which form they sell: free base, acetate or TFA salt.1 Unknown powders seized by Danish customs proved to be analogs of ipamorelin and modified GRF 1-29 carrying an extra glycine, and the authors urged testing labs to update their methods.16

The full profile, with side effects and regulatory status, is What is CJC-1295 + Ipamorelin?. What these studies measured is covered in CJC-1295 + Ipamorelin benefits and uses, and the DAC trials in more depth in CJC-1295 with DAC dosage. For how study doses are reported in general, see Peptide dosage basics.

More on CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin in the store

CJC-1295 + Ipamorelin for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

What doses were used in research studies?

Studies of CJC-1295 with DAC gave healthy adults single, weekly or every-other-week injections under the skin of 20 to 250 mcg/kg.41 Ipamorelin was given by vein: once at 4.21 to 140.45 nmol/kg in healthy men, and 0.03 mg/kg twice daily after bowel surgery.78 No human study has dosed CJC-1295 without DAC or the blend, and none of these figures is a dose for people.121718

What is the half-life of CJC-1295 without DAC and ipamorelin?

No human half-life has been published for CJC-1295 without DAC.1 The DAC version had an estimated half-life of 5.8 to 8.1 days in healthy adults, but FDA says those data cannot be carried over to the no-DAC form.41 IV ipamorelin had a terminal half-life of about 2 hours in healthy men, and there are no human data for ipamorelin injected under the skin.72

Do doses from CJC-1295 with DAC trials apply to this blend?

No. The DAC form carries an albumin-binding linker that kept it in the blood for days, and FDA treats it as a different substance whose pharmacology cannot be extrapolated to CJC-1295 without DAC.14 The DAC trials also gave CJC-1295 alone, never with ipamorelin, so neither their amounts nor the spacing between injections describe this blend.45

Has ipamorelin been studied as an injection under the skin?

Not in people. FDA found no human pharmacokinetic, pharmacodynamic or safety data for ipamorelin under the skin; the human studies used IV infusions, plus one nasal dose given to a single volunteer in an anti-doping study.214 Under-the-skin dosing appears only in animal studies, such as rat studies with 15 days of injections three times daily or 12 weeks by continuous pump.1011

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: CJC-1295-Related Bulk Drug Substances (FDA evaluation dated 11/15/2024). U.S. Food and Drug Administration, 2024.
  2. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, October 29, 2024: Ipamorelin-Related Bulk Drug Substances (FDA evaluation dated 8/19/2024). U.S. Food and Drug Administration, 2024.
  3. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski A et al.). Frontiers in Endocrinology, 2026.
  4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman SL et al.). Journal of Clinical Endocrinology and Metabolism, 2006.
  5. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (Ionescu M, Frohman LA). Journal of Clinical Endocrinology and Metabolism, 2006.
  6. NCT00267527: A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov (U.S. National Library of Medicine), 2006.
  7. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (Gobburu JV, Agersø H, Jusko WJ, Ynddal L). Pharmaceutical Research, 1999.
  8. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group). International Journal of Colorectal Disease, 2014.
  9. ClinicalTrials.gov NCT01280344: Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (API record). U.S. National Library of Medicine, ClinicalTrials.gov, 2017.
  10. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats (Johansen PB et al.). Growth Hormone and IGF Research, 1999.
  11. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats (Svensson J et al.). Journal of Endocrinology, 2000.
  12. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (PubMed abstract, PMID 11735244). Growth Hormone & IGF Research, 2001.
  13. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men (Soule S et al.). Journal of Clinical Endocrinology and Metabolism, 1994.
  14. Semenistaya E, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (PubMed abstract, PMID 25869809). Drug Testing and Analysis, 2015.
  15. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (Mayfield CK et al.). American Journal of Sports Medicine, 2026.
  16. Glycine-modified growth hormone secretagogues identified in seized doping material (Gajda PM et al.). Drug Testing and Analysis, 2019.
  17. ClinicalTrials.gov API search: ipamorelin CJC-1295 (no studies returned). ClinicalTrials.gov (U.S. National Library of Medicine).
  18. PubMed search: ipamorelin AND (CJC-1295 OR modified GRF) limited to clinical trial, randomized controlled trial and clinical study publication types (no results). NCBI PubMed (E-utilities).